Evolus, Inc. (0K16.L)

USD 14.58

(0.16%)

Inventory Summary of Evolus, Inc.

  • Evolus, Inc.'s latest annual inventory in 2023 was 10.99 Million USD , down -41.66% from previous year.
  • Evolus, Inc.'s latest quarterly inventory in 2024 Q2 was 13.38 Million USD , up 15.88% from previous quarter.
  • Evolus, Inc. reported annual inventory of 18.85 Million USD in 2022, up 969.92% from previous year.
  • Evolus, Inc. reported annual inventory of 1.76 Million USD in 2021, down -47.47% from previous year.
  • Evolus, Inc. reported quarterly inventory of 13.38 Million USD for 2024 Q2, up 15.88% from previous quarter.
  • Evolus, Inc. reported quarterly inventory of 17.62 Million USD for 2023 Q3, down -11.24% from previous quarter.

Annual Inventory Chart of Evolus, Inc. (2023 - 2015)

Historical Annual Inventory of Evolus, Inc. (2023 - 2015)

Year Inventory Inventory Growth
2023 10.99 Million USD -41.66%
2022 18.85 Million USD 969.92%
2021 1.76 Million USD -47.47%
2020 3.35 Million USD -47.65%
2019 6.4 Million USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%

Peer Inventory Comparison of Evolus, Inc.

Name Inventory Inventory Difference
uniQure N.V. 12.02 Million USD 8.533%
Agios Pharmaceuticals, Inc. 19.07 Million USD 42.346%
Amicus Therapeutics, Inc. 59.69 Million USD 81.577%
Atara Biotherapeutics, Inc. 9.7 Million USD -13.311%
bluebird bio, Inc. 22.91 Million USD 52.014%
Cara Therapeutics, Inc. 2.82 Million USD -289.862%
Imunon, Inc. - USD -Infinity%
Editas Medicine, Inc. - USD -Infinity%
IQVIA Holdings Inc. - USD -Infinity%
Mettler-Toledo International Inc. 385.86 Million USD 97.15%
Myriad Genetics, Inc. 20.1 Million USD 45.284%
Neurocrine Biosciences, Inc. 38.3 Million USD 71.285%
Supernus Pharmaceuticals, Inc. 77.4 Million USD 85.792%
Verastem, Inc. - USD -Infinity%
Walgreens Boots Alliance, Inc. 8.32 Billion USD 99.868%
Waters Corporation 516.23 Million USD 97.87%
Thermo Fisher Scientific Inc. 5.08 Billion USD 99.784%
Biogen Inc. 2.52 Billion USD 99.565%
Nektar Therapeutics 16.1 Million USD 31.694%
Perrigo Company plc 1.14 Billion USD 99.036%
Dynavax Technologies Corporation 53.29 Million USD 79.362%
Illumina, Inc. 587 Million USD 98.126%
Corbus Pharmaceuticals Holdings, Inc. - USD -Infinity%
Iovance Biotherapeutics, Inc. 10.37 Million USD -6.035%
Heron Therapeutics, Inc. 42.11 Million USD 73.883%
Unity Biotechnology, Inc. - USD -Infinity%
BioMarin Pharmaceutical Inc. 1.1 Billion USD 99.007%
Sangamo Therapeutics, Inc. - USD -Infinity%
Adicet Bio, Inc. - USD -Infinity%
Aclaris Therapeutics, Inc. - USD -Infinity%
Regeneron Pharmaceuticals, Inc. 2.58 Billion USD 99.574%
Esperion Therapeutics, Inc. 65.62 Million USD 83.241%
FibroGen, Inc. 41.56 Million USD 73.54%
Agilent Technologies, Inc. 1.03 Billion USD 98.933%
OPKO Health, Inc. 65.69 Million USD 83.26%
Homology Medicines, Inc. - USD -Infinity%
Geron Corporation - USD -Infinity%
Alnylam Pharmaceuticals, Inc. 89.14 Million USD 87.663%
Exelixis, Inc. 17.32 Million USD 36.512%
Viking Therapeutics, Inc. - USD -Infinity%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. - USD -Infinity%
Zoetis Inc. 2.56 Billion USD 99.571%
Axsome Therapeutics, Inc. 15.13 Million USD 27.334%
Abeona Therapeutics Inc. -2.44 Million USD 550.0%
Vertex Pharmaceuticals Incorporated 738.8 Million USD 98.511%
Kala Pharmaceuticals, Inc. - USD -Infinity%
Ionis Pharmaceuticals, Inc. 28.42 Million USD 61.309%
Sarepta Therapeutics, Inc. 322.85 Million USD 96.594%
Corcept Therapeutics Incorporated 7.73 Million USD -42.277%
Halozyme Therapeutics, Inc. 127.6 Million USD 91.381%
Blueprint Medicines Corporation 21.22 Million USD 48.179%
Insmed Incorporated 83.24 Million USD 86.789%
TG Therapeutics, Inc. 39.82 Million USD 72.383%
Incyte Corporation 62.97 Million USD 82.535%
Emergent BioSolutions Inc. 328.9 Million USD 96.656%